1 day Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth? Zacks

EXEL’s shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.

S&P 500